Wound Infection BacterialWIDENCT03883230
Wound Infection Detection Evaluation, WIDE
An observational study of Wound Infection Bacterial and Ulcer Foot, run by Cumbria Partnership NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
Chronic wounds, such as diabetic foot ulcers, place a huge burden on healthcare systems and can lead to complications with high morbidity, particularly if the wound if infected. In parallel, there is pressure to reduce the use of antibiotics in order to minimise the risk of antimicrobial resistance. Read more about this study
- Who is it for?
- Ages 18 to 110 years
- Conditions the study is for
- Wound Infection Bacterial, Ulcer Foot, Diabetic Foot
- What is being tested?
- GLYWD
- How many people
- 256 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 27 Jul 2017to 31 Jan 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 110 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with chronic non-infected Diabetic Foot Ulcers (DFU) or other chronic and delayed-healing wounds will be recruited into the study. Patients will be recruited from the adult population seen routinely by the evaluation clinical staff.
Who may be able to join
- - Adult patients aged > 18 years
- Patients with recurrent wounds, including multiple wounds, are eligible (including patients who have concluded participation in this study for one wound, but have another wound in another location).
- If infection occurs, and/or antibiotics applied, whilst in study then this is not deemed an exclusion criterion.
- DFU element: Clinical diagnosis of Diabetic Foot Ulcer (DFU) with wound duration > 30 days.
- Other Other chronic and delayed-healing wounds element: Clinical diagnosis of a chronic or delayed-healing wound, with the wound present for at least 6 weeks. To include:
- Pressure ulcer
Show all 10Show fewer
- Leg ulcer (can be venous, mixed or arterial in nature)
- Non-diabetic foot ulcer
- Post-operative wound
- Trauma or other non-surgical wounds
Who cannot join
- - Aged < 18 years
- Any reasons for the patient being unable to follow the protocol, including lack of mental capacity to consent to taking part in the study.
- The patient has concurrent (medical) conditions that in the opinion of the investigator may compromise patient safety or study objectives
- DFU element only:
- Confirmed and ongoing wound infection at baseline which is already being treated with systemic antibiotics.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Research & Development Department
Carlisle, Cumbria, CA1 3SX
About this study
Official title: A Multi-centre, Controlled, Prospective Cohort Study Investigating the Accuracy of the Glycologic Limited Test Kit to Detect Bacterial Infection in Chronic and Delayed-healing Wounds.
Chronic wounds, such as diabetic foot ulcers, place a huge burden on healthcare systems and can lead to complications with high morbidity, particularly if the wound if infected. In parallel, there is pressure to reduce the use of antibiotics in order to minimise the risk of antimicrobial resistance. The Glycologic wound detection kit (GLYWD) is a point-of-care test, designed to provide guidance to clinical staff as to whether a chronic wound is infected or not. In this prospective cohort study the premise of this mode-of-action is evaluated. GLYWD will be applied in conjunction with clinical opinion and microbiological testing to determine if there is concordance between the different diagnostic approaches, and if applicable how they may differ in certain patients' wounds.
Read the detailed description
The occurrence of diabetic foot ulcer (DFU) is a common complication of diabetes with enormous cost implications, totalling £650 million per year once associated morbidity is taken into account (NHS Diabetes report). Bacterial infection of wounds carries the risk of further degenerative complications including cellulitis, necrotising fasciitis, and sepsis (Grothier, 2015). Specific wounds, such as diabetic foot ulcers may lead to amputation if osteomyelitis develops. An additional undesirable effect of infection of wounds is that it delays - or stops altogether - the wound healing process (Halbert et al, 1992).
Detection of DFU infection remains reliant on clinical judgement. For example, imaging modalities such as MRI do not perform better than clinical appraisal in terms of sensitivity and specificity when it comes to detecting osteomyelitis (Dinh et al, 2008). O'meara and colleagues (2006) concluded from a systematic review on clinical examination, sample acquisition and sample analysis in DFUs that there is a lack of evidence regarding what samples should be taken and how they should be analysed. They did suggest that semi-quantitative sample analysis - a category that the Glycologic detection kit (called GLYWD) would fall under - may be a useful alternative to quantitative analysis. Quantitative detection of infection is still undertaken by swabbing the wound and then culturing the pathogens in a microbiology laboratory. Obtaining these results generally takes days; even molecular profiling does not give an instant result. Microbiological counts and species identification do not necessarily reflect infection as defined by other assessments, as demonstrated by Gardner et al (2014).
Clinical guidelines stipulate that the only available laboratory-based diagnostic option, microbiological testing, should only be used to identify the pathogen strain in clinically confirmed infection. Therefore, clinical opinion is the mainstay of predicting and diagnosing infection (NICE, 2008, 2015). The lack of a simple cost-effective and repeatable testing method may have three consequences: 1) lack of uniformity in diagnosis, due to differences in clinical judgement, which in turn may result in 2) over-diagnosis of infection with inappropriate prescription of antibiotics or antimicrobial dressings, or 3) late presentation of patients with systemic signs and spreading cellulitis or osteomyelitis requiring hospital admission and treatment with intravenous antibiotics or emergency surgery.
The provision of a rapid, reliable, sensitive and relatively low cost infection detection test kit for infection, which can be used at point-of-care, has the potential to provide the NHS with significant cost savings as well as improving the outcomes for patients. Therefore, in this study the Glycologic diagnostic wound infection detection test (GLYWD) is evaluated against clinical opinion and microbiological diagnostics to determine if it is an effective tool for the rapid detection of chronic wound infection.
- Being tested
- GLYWD
- Medical subject headings
- Foot Ulcer, Diabetic Foot
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GLYWDDiagnostic test
As mentioned in the group description, GLYWD is a plastic test tube and a chromatic test that contains two solutions. When combined with a wound exudate and incubated at RT, it will change colour to red if there is a pathological bacterial wound infection present.
| Study group | Role | What they receive |
|---|---|---|
| Patients with chronic wound | All patients will have a Glycologic infection detection test (GLYWD) taken. For this, a standard CE-marked sterile swab is used to take a wound exudate sample. This is then inserted in the GLYWD detection tube device. The device will contain two separate reagents, one in the clear plastic vial end and the other in the foil-sealed compartment. The sterile swab with the wound exudate sample will be pushed into the device, breaking the foil-sealed compartment and allowing the reagents to mix with the sample. the result of the test - to see if there is a bacterial infection present in the wound - is observed up to ten minutes later. Receives: Diagnostic Test: GLYWD |
What is being measured
The primary outcome is the main question the study is designed to answer.
GLYWD test result
Result of diagnostic testing of wound with GLYWD
Measured: 10 minutes
Secondary outcomes (2)
Microbiology result of wound swab
The wound will be assessed with standard microbiological techniques. After 2 days incubation at 37C and 5% CO2, the types of bacteria isolated and grown in the swab sample will be reported. This will be using standard Colony Forming Units (CFU)
Measured: 2 days
Clinician's wound characterization
A clinician's scoring of wound characteristics for infection (absent, possible infection, definite infection), and the three hallmark signs of infection, namely: erythema (-, +, ++) purulence (-, +, ++), odour (none, mild, moderate, severe)
Measured: 1 minute
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2019
- Study start27 Jul 2017
- Primary completion31 Dec 2019
- Study completion31 Jan 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Wound Infection BacterialStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 256 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cumbria Partnership NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Leon Jonker, PhD, Principal investigator, Cumbria Partnership NHS Trust, UK
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03883230
- Sponsor's protocol ID
- CP1713
- Acronym
- WIDE
- Status last verified
- Jul 2022
- First submitted
- 15 Feb 2019
- Last updated
- 22 Jul 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Not applicable. We'll share the anonymised raw data -with individual but not with personal identifiable data included- with the journal that we submit results to.
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-centre, Controlled, Prospective Cohort Study Investigating the Accuracy of the Glycologic Limited Test Kit to Detect Bacterial Infection in Chronic and Delayed-healing Wounds.
- ClinicalTrials.gov ID
- NCT03883230
- Acronym / sponsor ID
- WIDE / CP1713
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 256 participants (actual)
- Lead sponsor
- Cumbria Partnership NHS Foundation TrustUniversity, hospital or other
- Study start
- 27 Jul 2017 (actual)
- Primary completion
- 31 Dec 2019 (actual)
- Study completion
- 31 Jan 2020 (actual)
- First posted
- 20 Mar 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic wounds, such as diabetic foot ulcers, place a huge burden on healthcare systems and can lead to complications with high morbidity, particularly if the wound if infected. In parallel, there is pressure to reduce the use of antibiotics in order to minimise the risk of antimicrobial resistance. The Glycologic wound detection kit (GLYWD) is a point-of-care test, designed to provide guidance to clinical staff as to whether a chronic wound is infected or not. In this prospective cohort study the premise of this mode-of-action is evaluated. GLYWD will be applied in conjunction with clinical opinion and microbiological testing to determine if there is concordance between the different diagnostic approaches, and if applicable how they may differ in certain patients' wounds.
Detailed description
The occurrence of diabetic foot ulcer (DFU) is a common complication of diabetes with enormous cost implications, totalling £650 million per year once associated morbidity is taken into account (NHS Diabetes report). Bacterial infection of wounds carries the risk of further degenerative complications including cellulitis, necrotising fasciitis, and sepsis (Grothier, 2015). Specific wounds, such as diabetic foot ulcers may lead to amputation if osteomyelitis develops. An additional undesirable effect of infection of wounds is that it delays - or stops altogether - the wound healing process (Halbert et al, 1992).
Detection of DFU infection remains reliant on clinical judgement. For example, imaging modalities such as MRI do not perform better than clinical appraisal in terms of sensitivity and specificity when it comes to detecting osteomyelitis (Dinh et al, 2008). O'meara and colleagues (2006) concluded from a systematic review on clinical examination, sample acquisition and sample analysis in DFUs that there is a lack of evidence regarding what samples should be taken and how they should be analysed. They did suggest that semi-quantitative sample analysis - a category that the Glycologic detection kit (called GLYWD) would fall under - may be a useful alternative to quantitative analysis. Quantitative detection of infection is still undertaken by swabbing the wound and then culturing the pathogens in a microbiology laboratory. Obtaining these results generally takes days; even molecular profiling does not give an instant result. Microbiological counts and species identification do not necessarily reflect infection as defined by other assessments, as demonstrated by Gardner et al (2014).
Clinical guidelines stipulate that the only available laboratory-based diagnostic option, microbiological testing, should only be used to identify the pathogen strain in clinically confirmed infection. Therefore, clinical opinion is the mainstay of predicting and diagnosing infection (NICE, 2008, 2015). The lack of a simple cost-effective and repeatable testing method may have three consequences: 1) lack of uniformity in diagnosis, due to differences in clinical judgement, which in turn may result in 2) over-diagnosis of infection with inappropriate prescription of antibiotics or antimicrobial dressings, or 3) late presentation of patients with systemic signs and spreading cellulitis or osteomyelitis requiring hospital admission and treatment with intravenous antibiotics or emergency surgery.
The provision of a rapid, reliable, sensitive and relatively low cost infection detection test kit for infection, which can be used at point-of-care, has the potential to provide the NHS with significant cost savings as well as improving the outcomes for patients. Therefore, in this study the Glycologic diagnostic wound infection detection test (GLYWD) is evaluated against clinical opinion and microbiological diagnostics to determine if it is an effective tool for the rapid detection of chronic wound infection.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with chronic wound | – | Diagnostic Test: GLYWDAll patients will have a Glycologic infection detection test (GLYWD) taken. For this, a standard CE-marked sterile swab is used to take a wound exudate sample. This is then inserted in the GLYWD detection tube device. The device will contain two separate reagents, one in the clear plastic vial end and the other in the foil-sealed compartment. The sterile swab with the wound exudate sample will be pushed into the device, breaking the foil-sealed compartment and allowing the reagents to mix with the sample. the result of the test - to see if there is a bacterial infection present in the wound - is observed up to ten minutes later. |
Who may qualify
- Ages
- 18 to 110 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with chronic non-infected Diabetic Foot Ulcers (DFU) or other chronic and delayed-healing wounds will be recruited into the study. Patients will be recruited from the adult population seen routinely by the evaluation clinical staff.
Key inclusion criteria (10 listed)
- - Adult patients aged > 18 years
- Patients with recurrent wounds, including multiple wounds, are eligible (including patients who have concluded participation in this study for one wound, but have another wound in another location).
- If infection occurs, and/or antibiotics applied, whilst in study then this is not deemed an exclusion criterion.
- DFU element: Clinical diagnosis of Diabetic Foot Ulcer (DFU) with wound duration > 30 days.
- Other Other chronic and delayed-healing wounds element: Clinical diagnosis of a chronic or delayed-healing wound, with the wound present for at least 6 weeks. To include:
Key exclusion criteria (5 listed)
- - Aged < 18 years
- Any reasons for the patient being unable to follow the protocol, including lack of mental capacity to consent to taking part in the study.
- The patient has concurrent (medical) conditions that in the opinion of the investigator may compromise patient safety or study objectives
- DFU element only:
- Confirmed and ongoing wound infection at baseline which is already being treated with systemic antibiotics.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GLYWDAs mentioned in the group description, GLYWD is a plastic test tube and a chromatic test that contains two solutions. When combined with a wound exudate and incubated at RT, it will change colour to red if there is a pathological bacterial wound infection present. | Diagnostic test | Patients with chronic wound |
Primary outcome
GLYWD test result
Time frame: 10 minutes
Result of diagnostic testing of wound with GLYWD
2 secondary outcomes
Microbiology result of wound swab
Time frame: 2 days
Clinician's wound characterization
Time frame: 1 minute
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2022.
- Individual participant dataSharing planned: No. Not applicable. We'll share the anonymised raw data -with individual but not with personal identifiable data included- with the journal that we submit results to.
Related trials for Wound Infection Bacterial
Enrolling by invitationObservational study
Prevention of Vaginal Cuff Infection After Hysterectomy by Addition of Vaginal Clindamycin
Surgical Site Infection, Vaginal Cuff Cellulitis
Not yet recruitingEarly Phase 1
Silymarin Versus N-Acetylcysteine as Protective Effect Against Anti-tuberculosis Drugs Induced Liver Injury.
Drug-Induced Acute Liver Injury, Tuberculosis (TB)
Not yet recruitingObservational study
Differentiating True Nephrotoxicity From Pseudo-nephrotoxicity: A Prospective Comparative Study of Vancomycin Plus Piperacillin-Tazobactam vs. Meropenem Using Serum Creatinine and Cystatin-C
Nephrotoxicity, Bacterial Infections
Not yet recruitingPhase 4
Emerging Indications for Hyperbaric Oxygen Treatment
Post-COVID-19 Condition, Ulcerative Colitis
Not yet recruitingObservational study
Urinary Bladder Matrix (UBM) Registry
Tissue Repair, Soft Tissue Reconstruction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Leon Jonker, PhD principal investigator
Cumbria Partnership NHS Trust, UK
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Wound Infection Bacterial and Ulcer Foot, run by Cumbria Partnership NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
GLYWD test result (time frame: 10 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2022.